Abstract
Introduction: Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Conclusion: Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Keywords: Renal denervation, resistant hypertension, blood pressure response, Symplicity HTN-3, BP, cardiovascular disease.
Graphical Abstract
Current Vascular Pharmacology
Title:Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Volume: 16 Issue: 1
Author(s): Costas Tsioufis*, Kyriakos Dimitriadis, Athanasios Kordalis, Michalis Doumas, Dimitris Konstantinidis, Theodoros Kalos, Felix Mahfoud, Vasilios Papademetriou and Dimitrios Tousoulis
Affiliation:
- First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens,Greece
Keywords: Renal denervation, resistant hypertension, blood pressure response, Symplicity HTN-3, BP, cardiovascular disease.
Abstract: Introduction: Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Conclusion: Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Export Options
About this article
Cite this article as:
Tsioufis Costas *, Dimitriadis Kyriakos, Kordalis Athanasios , Doumas Michalis , Konstantinidis Dimitris , Kalos Theodoros, Mahfoud Felix , Papademetriou Vasilios and Tousoulis Dimitrios , Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666170426151649
DOI https://dx.doi.org/10.2174/1570161115666170426151649 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief
Current Pharmaceutical Design Rationale and Design of the ACS-BP Study: Prognostic Value of In-Hospital Blood Pressure and Indices of Atherosclerosis in Acute Coronary Syndromes
Current Vascular Pharmacology Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets
Current Medicinal Chemistry Anti-Inflammatory Intervention for Acute Liver Failure: Recent Patents and Future Targets
Recent Patents on Biomarkers Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews Fetal Arterial Changes in Response to Maternal Cigarette Smoking: Revisiting the Natural History of the Earliest Stage of Atherosclerosis
Current Cardiology Reviews Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators
Current Medicinal Chemistry Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics
Current Cancer Drug Targets